High-performance mRNA engineered for superior expression, enhanced stability, reduced immunogenicity, and seamless GMP-scale manufacturability.
Our mRNA Design & Optimization service empowers pharmaceutical companies, biotechnology innovators, and therapeutic development teams with fully engineered, high-efficiency mRNA sequences optimized for commercial use. Leveraging AI-driven mRNA sequence design, codon and GC engineering, advanced UTR architecture optimization, RNA folding and ΔG modeling, immunogenicity reduction strategies, and manufacturability-focused RNA engineering, we deliver next-generation mRNA constructs that consistently demonstrate stronger protein expression, improved in-vivo stability, and exceptional compatibility with IVT and GMP-scale manufacturing workflows. Whether you are developing mRNA vaccines, gene-editing payloads (Cas9/Cas12/ABE/BE), protein or antibody replacement therapies, immuno-oncology programs, or mRNA-based cell therapy payloads, our platform provides a complete end-to-end solution—from target evaluation and computational optimization to optional in-vitro validation, research-grade IVT synthesis, and CDMO-ready final deliverables. This ensures faster R&D timelines, lower development risk, and a direct path to high-quality, manufacturable, and therapeutic-grade mRNA sequences.
mRNA Design & Optimization MethodDeveloping therapeutic-grade mRNA is far more complex than assembling a coding sequence.
Most mRNA constructs fail to achieve optimal expression, stability, or manufacturability due to poor UTR design, unfavorable secondary structures, high innate immunogenicity, or low IVT productivity. These issues can significantly delay R&D timelines, increase development costs, and compromise downstream manufacturability for preclinical or GMP production.
Common challenges include:
Insufficient protein expression resulting from suboptimal UTR/ORF architecture
Instability and rapid degradation in vivo, limiting therapeutic duration
High innate immune activation, reducing tolerability and editing/therapeutic efficiency
Secondary structure bottlenecks that impair translation initiation
Poor manufacturability with low IVT yield or high dsRNA impurities
Difficulties transitioning into CDMO/GMP workflows due to non-scalable sequence designs
A robust mRNA design and optimization strategy ensures that your therapeutic candidates are built on a strong scientific foundation—highly expressible, stable, safe, scalable, and ready for development.
We provide a full suite of specialized mRNA design, optimization, and development services tailored for pharmaceutical companies and advanced biotechnology programs. Each service can be delivered independently or as an integrated, end-to-end solution.
Core Services:
Value: Create the most efficient, stable, scalable mRNA sequence based on your target protein.
Core Services:
Value: Improve in-vivo persistence, translational efficiency, and therapeutic performance.
Core Services:
Value: Enhance tolerability and reduce innate immune activation.
| Modified Nucleoside | Purpose | Benefits | Common Use Cases |
| m1Ψ | Reduce innate immune activation | Improved tolerability | Vaccines, protein therapies |
| 5-moU | Lower immunogenic motifs | Higher expression | Gene editing payloads |
| N1-Me-Pseudouridine | Enhance stability | Longer duration | Rare disease therapies |
Core Services:
Value: Eliminate structural bottlenecks that reduce expression or cause immune activation.
Core Services:
Value: Experimental validation of predicted performance—de-risk early decisions.
Core Services:
Value: A final sequence ready for CDMO transfer, GMP synthesis, and IND-enabling studies.
| Service Module | What's Included | Key Benefits |
| Sequence Design | UTR/ORF design, codon optimization, structure modeling | Higher expression, predictable performance |
| Stability Optimization | Poly(A) tuning, degradation hotspot removal | Longer duration, in vivo stability |
| Immunogenicity Reduction | Modified nucleoside strategy, motif removal | Reduced innate immune activation |
| In-Silico Analysis | Folding maps, ΔG modeling, ribosome accessibility | De-risked translation efficiency |
| In-Vitro Testing | Expression assays, purity, dsRNA assessment | Early functional validation |
| Manufacturing-Ready Finalization | GMP-compatible sequence, scalability checks | Smooth CDMO tech transfer |
Before we begin designing or optimizing any mRNA sequence, we follow a structured, data-driven workflow that ensures scientific rigor, predictable performance, and seamless downstream manufacturability. Our process combines computational modeling, RNA structural engineering, and therapeutic development expertise to move your candidate from early concept to a fully optimized, CDMO-ready mRNA construct. Each step is designed to reduce risk, accelerate timelines, and generate high-quality deliverables that support preclinical development.
Protein domain design
Translational feasibility modeling
Expression potential assessment
Deliverable: Feasibility Report + Initial Strategy
Multi-candidate generation
Scoring based on structure, expression, manufacturability
Deliverable: Top 3-10 Optimized Sequence Candidates
Secondary structure maps
Ribosome accessibility (RiboScore)
Immunogenic motif screening
Deliverable: Structural QC Report
Protein expression assays
mRNA purity & IVT productivity assessment
Deliverable: Experimental Expression Report
Codon fine-tuning
UTR harmonization
dsRNA minimization strategy
Deliverable: GMP-Ready Final Sequence + Tech Transfer Package
Our machine-learning engine integrates structural biology, ribosome accessibility modeling, and large-scale expression data to deliver optimized sequences across:
Result: Up to 8-20× increase in protein expression.
Enhance durability and in-vivo persistence through:
Ensures longer protein expression windows and improved pharmacological performance.
Designed to align with global CDMO requirements:
Your sequence moves smoothly from design → synthesis → formulation → IND.
| Capability Category | Our Offering | Industry Benchmark | Client Benefit |
| AI-Driven Design | Advanced sequence modeling | Limited | Faster optimization, higher performance |
| Structural Analysis | Full UTR/ORF/ΔG modeling | Partial | Lower risk, more predictable outcomes |
| Immunogenicity Reduction | Modified nucleoside strategy | Limited | Safer therapeutic profiles |
| IVT Synthesis | Preclinical-grade | Varies | Quick experimental validation |
| GMP Readiness | Manufacturing-ready design | Not common | Smoother CDMO tech transfer |
A high-quality mRNA therapeutic candidate depends not only on sequence design, but also on the clarity, traceability, and scientific rigor of the technical documentation that accompanies it. To support pharmaceutical and biotech teams across R&D, preclinical development, CMC, and CDMO collaboration, we provide a comprehensive deliverable package that consolidates all design rationale, structural analyses, manufacturability assessments, and recommended QC strategies. This ensures your optimized mRNA sequence is fully explainable, scientifically validated, and ready for both experimental testing and GMP-scale manufacturing. Below is a detailed overview of what you will receive:
| Deliverable | Contents / Scope | Value for Pharma / Biotech Teams |
| Optimized mRNA Sequence Package | Final optimized mRNA sequence(s) including 5′UTR, ORF, 3′UTR, poly(A) design; manufacturability-ready architecture; optional variants for different expression profiles | Ready-to-use, high-performance mRNA sequences for direct synthesis, preclinical testing, and tech transfer |
| UTR Architecture & Design Rationale | Design logic for 5′UTR/3′UTR, regulatory motifs, translation initiation strategy, cap & tail coordination; comparison to baseline/non-optimized design | Transparent scientific justification for regulatory discussions, internal review, and cross-team alignment |
| Codon Optimization & GC Profile Report | Codon usage analysis, GC content strategy, rare codon handling, avoidance of problematic motifs; comparison vs wild-type sequence | Shows how expression efficiency has been engineered, facilitating internal CMC, biology, and management review |
| RNA Structure & Stability Dossier | Secondary structure maps, ΔG profiles, ribosome accessibility analysis, folding hotspots, predicted half-life impact | De-risks translation and stability issues; supports decision-making for candidate selection and risk assessment |
| Immunogenicity & Innate Immune Risk Assessment | TLR/RIG-I-sensitive motif screening, dsRNA risk factors, impact of modified nucleosides (e.g., m1Ψ), sequence-level risk ranking | Helps safety, non-clinical, and regulatory teams understand innate immune risk and mitigation strategies |
| Manufacturability & IVT Performance Assessment | Predicted IVT yield, dsRNA formation tendency, purification compatibility (e.g., HPLC), scalability considerations for preclinical and GMP runs | Ensures the sequence is practical for CDMO/GMP manufacturing, reducing surprises during scale-up |
| QC & Analytical Recommendations | Suggested QC panel (dsRNA, purity, capping efficiency, identity), recommended analytical methods and acceptance criteria ranges | Gives CMC and QC teams a clear starting point for method development and release testing strategies |
| Delivery System / LNP Compatibility Notes (Optional) | Sequence-level considerations for LNP or alternative delivery systems (length, structure, release dynamics); high-level formulation compatibility notes | Connects mRNA design with your delivery strategy, improving overall product performance |
| In-Vitro Expression Data Package (Optional) | Cell-based expression assays, dose–response curves, time-course stability, mRNA quality metrics (purity, dsRNA) | Provides experimental evidence to support go/no-go decisions and de-risk preclinical studies |
Our optimized mRNA sequences support a wide spectrum of therapeutic programs. Each application is engineered for high expression, improved durability, reduced immunogenicity, and CDMO-ready manufacturability.
mRNA vaccine programs benefit significantly from enhanced translation efficiency, stability, and immune modulation.
Enable transient or sustained delivery of therapeutic proteins directly in vivo.
(Cas9, Cas12, Base Editors, Prime Editors)
Gene editing tools require potent but tightly controlled mRNA expression.
(CAR-T, CAR-NK, TCR-T)
Engineered mRNA plays a critical role in ex vivo or in vivo cell programming.
Rare disease programs often require long-lasting expression with minimal immunogenicity.
Developing high-performance mRNA therapeutics requires deep scientific insight, engineering precision, and a partner that understands the demands of modern drug development. Whether you are advancing a vaccine, gene-editing payload, antibody replacement therapy, or next-generation cell therapy program, our platform is designed to support your success at every stage — from concept design to preclinical readiness and scalable manufacturing.
